drugset / Trial / NCT05638451
Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of Sintilimab in combination with Bevacizumab and Temozolomide in subjects with recurrent glioblastoma.
Timeline
- Start
- 2023-05-01
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | — |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | — |
| Subject | Temozolomide | Small molecule | 200 mg/m2 | — |